Navigation Links
Study shows carvedilol is effective in preventing variceal bleeding in cirrhotic patients
Date:8/19/2009

Patients with cirrhosis are at risk for developing portal hypertension that can lead to the formation, dilation, and rupture of esophageal varices. The annual incidence of esophageal varices is approximately 5% and one third of those will bleed.

In a recent study, researchers from the University of Edinburgh determined carvedilol was more effective in the prevention of variceal hemorrhaging than variceal band ligation (VBL), a common treatment used for the past 20 years. The results of the first clinical trial to test carvedilol for prevention of variceal hemorrhage are available in Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

Dhiraj Tripathi and colleagues at the Royal Infirmary of Edinburgh enlisted 152 cirrhotic patients with grade II or larger esophageal varices that had not bled in this study. Researchers treated 77 patients with carvedilol, a non-cardioselective beta-blocker (NSBB) marketed under the trade name Eucardic (Roche), while 75 patients underwent VBL every two weeks until eradication. Patients were administered carvedilol orally at a starting dose of 6.25 mg per day, increasing to a target dose of 12.5 mg per day.

Results showed 10% of patients receiving carvedilol and 23% of patients treated by VBL experienced variceal bleeding during the follow-up period. There was no difference in survival rates between the two groups. "The greater efficacy of carvedilol in the prevention of the first variceal bleed is an important finding of this study," said Dr. Tripathi. "No other randomized trial has demonstrated drug therapy to have an advantage over VBL."

While researchers concluded carvedilol had greater effectiveness in treating portal hypertension than endoscopic therapy, there were limitations to their study. "Measurements of hepatic venous-pressure gradient (HVPG) were not included as part of the study, making it difficult to determine if the benefit of carvedilol was due to a greater HVPG response or failure of the VBL, noted Dr. Jaime Bosch of the Hepatic Hemodynamic Laboratory Hospital Clinic in Barcelona, Spain in his editorial published in the September issue of Hepatology. HVPG is a standard measure used to determine portal vein pressure with variceal bleeding occurring at gradients of + 12 mm HG.

Propranolol, another NSBB drug commonly used to treat portal hypertension, was not included as part of this study. "Further studies are required to assess whether carvedilol is a better option than standard NSBB," added Dr. Bosch.


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning
2. Thomson Reuters Study Finds Impact of Recession Easing on U.S. Hospitals
3. Retirees health-care benefits at risk, study warns
4. Lilly Reports on Outcome of Phase III Study of Arzoxifene
5. New study finds links between video-game playing and health risks in adults
6. Gen-Probe Begins U.S. Clinical Study of APTIMA(R) Trichomonas Vaginalis Assay on the TIGRIS(R) System
7. Study shows how to boost value of Alzheimers-fighting compounds
8. Low-income kids report first sexual intercourse at 12 years old in new national study
9. Excessive exercise can be addicting, new study says
10. New study expands the list of hazardous chemicals in smokeless tobacco
11. Summer heat increases risk of amniotic fluid level deficiency, Ben-Gurion University study reveals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... Patel M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is ... Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), ... labor and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding ... the hospital and decide to donate. , “Women’s Hospital at Renaissance has been ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
(Date:4/28/2017)... ... 2017 , ... Bill Howe started his sewer and drain company in 1980 ... joined the team, the Bill Howe brand was born and they began cultivating their ... back to the San Diego community in which they worked, lived and were raising ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: